HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Lung metastatic load limitation with hyperbaric oxygen.
Abstract: Despite some theoretical concern about cancer-enhancing effects ofhyperbaric oxygen (HBO2) therapy, it is frequently administered to cancer patients. We evaluated the growth of murine breast cancer cells in the lung after hyperbaric oxygen treatment in an...
The life-saving effect of hyperbaric oxygenation during early-phase severe blunt chest injuries.
Abstract: The effect of hyperbaric oxygenation (HBO2) on survival during the early phase of severe blunt chest injury (BChI) has not been elucidated. Our aim was to investigate this effect on human victims of BChI. We monitored cardiac index (CI), stroke volume index...
Clinical Trial – Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck
This research is being done because we do not know the best treatment for advanced Squamous
Cell Carcinoma of the Head and Neck. These cancers have been treated with a combination of
surgery, radiation and chemotherapy in varying combination. When the tumor is inoperable,
radiation therapy is used with or without chemotherapy in the hope of curing the tumor.
Recently, it has become recognized as generalized knowledge that cancer cells are hypoxic
(low oxygen concentration). Because of the low oxygen concentrations, many cancer treatments
have not been successful. The theory behind this study is to give oxygen to patients prior to
chemotherapy and radiation in hopes of generating greater results in killing cancer cells.
The purpose of this study has two main objectives. The primary objective is to determine
patient tolerance to each arm of the trial.
The second objective is to determine the feasibility of treatment delivery and acute
toxicities associated with each regimen.
It is our intention to undertake a randomized and controlled trial should this Phase I trial
prove successful in terms of patient tolerance.


